Coegin Pharma’s strategy is to build a risk balanced pipeline through acquisition of product candidates in pre-clinical and early stages of development. We are actively seeking strategic collaborations with researchers and companies to enable and accelerate the pipeline of Coegin Pharma.
We are flexible in deal structuring which can include conventional licensing, partnerships, joint ventures, option agreements and others. We recognize and support the interest of many entrepreneurs and universities in forming new companies around their inventions.
Coegin Pharma will seek exit opportunities following clinical proof of concept and we are actively supporting our portfolio companies in identifying and executing strategic partnerships.
If you want to know more about the specific assets and portfolio companies, please visit:
Please contact Kristian Lykke Fick, CCO of Coegin Pharma AB via [email protected].